Platelet Transfusion Refractoriness
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Cell Therapy
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Keymed BiosciencesCM313
BiocorpCAR-T infusion
Clinical Trials (2)
Total enrollment: 130 patients across 2 trials
Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness
Start: Mar 2025Est. completion: Nov 2027110 patients
Phase 1/2Recruiting
Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL
Start: Apr 2021Est. completion: Mar 202420 patients
Phase 1/2Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 130 patients
Cell Therapy is the dominant modality (100% of programs)
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.